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Abstract: It has been suggested that soluble urokinase plasminogen activator (suPAR) can be used as a marker of disease severity and 
risk of mortality in sepsis. The aim with the present study was to compare plasma levels of suPAR in patients with severe sepsis to 
control subjects and correlate it with the level of inflammatory activation, severity and mortality. Samples were collected from 27 sepsis 
patients at the intensive care unit (ICU), Lund, Sweden; 90-day mortalities were registered. The suPAR level was significantly elevated 
in sepsis patients compared to controls, but not significantly higher in nonsurvivors than survivors. Plasma levels of suPAR did correlate 
weakly with the SOFA score and myeloperoxidase (MPO) but not with CRP, PCT, IL-6 or IL-10 in patients with severe sepsis. The weak 
correlation between suPAR and other inflammatory markers might suggest that suPAR reflects general activation of the immune system 
rather than exerting inflammatory actions.
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Introduction
Sepsis is a clinical syndrome defined as a systemic 
inflammatory  response  to  infection;  severe  sepsis, 
which is characterised by failing vital functions is 
a major cause of mortality in the intensive care unit 
(ICU).1 The diagnosis of sepsis and evaluation of its 
severity is complicated. A standardised assessment 
tool to identify patients who are at higher risk of a 
poor, or fatal even, outcome would be of high value to 
ensure the optimal use of health care resources.2,3
Biomarkers,  biological  molecules  that  are  char-
acteristics of normal or pathogenic processes can be 
useful indicators to clinicians. An ideal biomarker for 
identifying patients that need more intense   monitoring 
and  treatment  should  be  both  accurate  and  readily 
obtainable bedside. The two biomarkers that have been 
most widely studied and used in patients with severe 
sepsis are the C-reactive protein (CRP) and procal-
citonin (PCT).4–6 The urokinase plasminogen activa-
tor receptor (uPAR) is expressed on most leucocytes 
including  neutrophils,  lymphocytes,  monocytes  and 
macrophages,  which  are  crucially  important  in  the 
pathogenesis of sepsis. The interaction of uPAR with 
its ligand, the urokinase plasminogen activator (uPA), 
results in numerous immunologic events including cell 
migration,  adhesion,  proliferation  and    fibrinolysis.7 
Through inflammatory stimulation, uPAR is cleaved 
from the cell surface to the soluble form of the recep-
tor,  suPAR.7  Recently,  suPAR  has  been  suggested 
as  a  novel  prognostic  marker  to    identify  high-risk 
patients.8 In healthy individuals, suPAR levels are low 
and quite stable while the concentration increases in 
  conditions  that  involve  immune  activation.9  Several 
studies   indicate that an elevated suPAR level in plasma 
is associated with a negative outcome in critically ill 
patients  with  systemic  inflammatory  response  syn-
drome (SIRS), bacteriemia, sepsis, and septic shock 
and predict mortality in these patients.8,10–12 However, 
studies have also showed that suPAR does not appear 
to be superior to other biomarkers like CRP and PCT, 
in diagnosing sepsis.4,13
The  aim  with  the  present  study  was  to  investi-
gate the relationship between suPAR and the more 
commonly used clinical biomarkers CRP and PCT 
as  well  as  the  inflammatory  markers  IL-6,  IL-10, 
and myeloperoxidase (MPO) in patients with severe 
  sepsis. In   addition, we investigated if plasma   levels 
of  suPAR  can  predict  mortality  in  patients  with 
severe sepsis and if suPAR levels correlate with total 
Sequential Organ Failure Assessment (SOFA) scores, 
a sepsis mortality risk algorithm including multiple 
laboratory and clinical measures.
Materials and Methods
Patients
The patient material of the present study has been used 
in another already published study.14 The local research 
ethics committee approved the project and informed 
consent was obtained from patients or next of kin of 
the unconscious patients. Sepsis patients admitted to 
the ICU of Lund University Hospital, Sweden, between 
23 March 2004 and 7 December 2007 were included. 
All patients fulfilled at least 2 out of 4 criteria for SIRS, 
had a suspected or verified underlying infection and 
respiratory  and/or  circulatory  dysfunctions  requiring 
intensive care. Therefore, they fulfilled the criteria for 
severe sepsis or septic shock. Severity of organ dys-
function was defined with the SOFA score on the basis 
of measurements during the first 24 h of   admission. 
The  mortality  rate  within  90  days  after  admission 
was   registered. The median age of the septic patients 
was 65 years (range, 28–87 years; n = 27); 10 males 
and  17  females.  Survival  of  the  septic  patients 
in  90  days  post  submission  to  the  ICU  was  56% 
(15/27 patients).   Controls consisted of patients sched-
uled for   neurosurgery. Informed consent was obtained. 
None of the control patients had ongoing steroid treat-
ment. The median age of the controls was 61.5 years 
(range, 22–85 years; n = 22); 11 males and 11 females.
Sample collection
Within 24 h after admission to the ICU, blood samples 
were drawn from an already existing arterial catheter 
and were collected in EDTA-treated vacuettes. In six 
patients, additional blood samples were obtained 4 days 
later. Arterial blood samples from the control group were 
similarly  drawn  before  induction  of  anesthesia. The 
samples were immediately centrifuged for 10 minutes 
at 800 g at room temperature. The plasma supernatants 
were removed and stored at −70 °C until analysis.
Measurements of PcT and crP
PCT  was  measured  in  the  plasma  samples  using 
an  immunoluminometric  assay  from  BRAHMS suPAr in severe sepsis
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  (Henningsdorf, Germany) according to the manufacturer’s 
instructions. CRP concentration in venous blood was 
measured by routine latex-enhanced immunoturbidi-
metry (Roche Diagnostics).
eLISA assays
Plasma suPAR concentrations were analysed using 
a  commercially  available  enzyme  immunoassay 
(suPARnostic™, Virogates, Copenhagen, Denmark) 
according  to  the  manufacturer’s  instructions.  The 
assay  is  a  double  monoclonal  antibody  sandwich 
assay that measures all circulating suPAR, including 
full-length and cleaved forms of the receptor.
IL-6 and IL-10 levels were quantified using R&D 
Systems  High  Sensitivity  ELISA  according  to  the 
manufacturer’s instructions. MPO levels were quanti-
fied using an ELISA from Diagnostics Development, 
Uppsala, Sweden.
Statistical analysis
The differences in the plasma levels of suPAR between 
patients and controls, men and women, and between 
survivors and nonsurvivors were assessed using the 
Wilcoxon rank sum test. The difference between lev-
els at admission compared to the four-day samples 
was assessed with the Wilcoxon signed rank test. Cor-
relations between suPAR and the other inflammatory 
markers or age were calculated with linear regression 
on  log-transformed  data.  Differences  and  correla-
tions were considered as statistically significant when 
P , 0.05. 
Results
Patient characteristics
A total of 27 patients fulfilling at least two out of four 
SIRS criteria were included in this study. Patient char-
acteristics are summarized in Table 1. Medians of IL-6, 
IL-10, MPO and PCT were higher in patients with 
severe sepsis compared to controls (P , 0.001). In the 
sepsis patients, the levels of these inflammatory mark-
ers had decreased at day 4 compared with the levels at 
admission (P , 0.01) (data not shown). Blood culture 
was positive for E. coli in four patients,   Streptococcus 
pneumoniae  species  in  four  patients,  Enterococcus 
species in three patients, coagulase-negative staphy-
lococci in two patients,   pseudomonas species in one 
patient and enterobacter species in one patient. One 
of  the  patients  had  positive  blood  culture  for  both 
enterococcus and enterobacter   species. In twelve of 
the patients, the blood culture was negative.
Plasma suPAr
As depicted in Figure 1A, the median plasma suPAR 
level of patients with severe sepsis was significantly 
higher (P , 0.001) than that of the controls. The plasma 
level  of  suPAR  did  not  significantly  correlate  with 
mortality (Fig. 1B) although the median suPAR values 
were higher (n.s.) in non-survivors (15.4 ng/mL, range 
Table 1. Patient characteristics. 
sepsis control
Patients 27 22
Age, years 65 (28–87) 61.5 (22–85)
Male/female 10/17 11/11
Survival rate, % 56
crP, mg/L 219 (54–542,  
n = 22)
PcT, ng/mL 47.2 (0.5–445) 0.013 (0.003–0.11)
IL-6, pg/mL 2 348 (159– 
494 575)
0.5 (0.2–0.5)
IL-10, pg/mL 122 (5–857) 3.6 (0.9–17.0)
MPO, ng/mL 255 (54–2 000) 53 (35–184)
suPAr, ng/mL 12.2 (5.9–36.1) 2.5 (1.5–6.2)
renal SOFA  
score
2 (0–4, n = 20)
Total SOFA 
score
14 (5–18, n = 24)
note: Data are medians, with range in parenthesis.
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Figure 1. Plasma levels of suPAr in patients with severe sepsis, and 
controls. 
notes: P-values refer to statistically significant differences in median 
levels of sepsis patients compared to controls, between deceased and 
surviving sepsis patients at 90 days after admission or of sepsis patients at 
day 4 compared to the day of admission. The circles represent individual 
patients and the median is indicated with a horizontal line. In (c), open 
circles represent surviving patients. 
Abbreviation: n.s., not significant.gustafsson et al
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6.8–36.1, n = 12) compared to survivors (11.7 ng/mL, 
range 5.9–25.5, n = 15). The suPAR level of patients 
with  severe  sepsis  four  days  after  submission  had 
not changed significantly compared with the level at 
admission (16.9 ng/mL, range 8.6–36.5 vs. 14.6, range 
8.4–38.2, n = 6) (Fig. 1C). Plasma suPAR levels did 
not  correlate  with  age  or  gender,  neither  in  sepsis 
patients, nor in controls (data not shown).
correlation between levels of suPAr, 
mediators of inflammation and SOFA 
scores
No significant correlation was found between plasma 
levels of suPAR and the levels of CRP, PCT, IL-6 
or IL-10 (Fig. 2A–D). The plasma suPAR levels of 
patients  with  severe  sepsis  correlated  weakly  with 
admission SOFA scores (P = 0.05) (Fig. 3A) but not 
with renal SOFA scores. SOFA scores also correlated 
with levels of PCT (P , 0.05) but not with CRP or 
mortality.  suPAR  levels  correlated  with  the  levels 
of  the  neutrophil  granule  protein  MPO  (P  =  0.05) 
(Fig. 3B).
Discussion
Despite  the  relatively  small  number  of  patients 
included in this study, we found significantly higher 
levels of plasma suPAR in patients with severe sepsis 
compared to non-sepsis patients upon admission to 
the ICU. The result suggests that suPAR is a pow-
erful marker of inflammation in patients with sepsis, 
concordant with previous studies.8,10–12 We measured 
suPAR plasma concentrations upon admission to the 
ICU, at the start of intensive care treatment, and in 
six patients after four days. In contrast to CRP, PCT, 
MPO, IL-6, and IL-10, plasma suPAR concentrations 
did not significantly differ within the first four days 
of ICU treatment. This suggests that the clearance of 
suPAR is low and/or that the production and release 
persists  over  a  longer  time  compared  to  the  other 
inflammatory  markers.  It  has  been  demonstrated 
that suPAR plasma concentrations are correlated to 
renal function, suggesting that failing renal clearance 
might additionally contribute to elevated circulatory 
suPAR.13 In the present study no correlation between 
renal SOFA and suPAR levels was found. Our study 
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Figure 2. correlation between suPAr and crP (A, P = 0.53, r = 0.15), IL-6 (B, P = 0.84, r = 0.040), IL-10 (c, P = 0.93, r = 0.019), and PcT (D, P = 0.98, 
r = 0.0062), respectively. 
notes: The red circles represent sepsis patients and the blue circles controls. crP was not measured in the controls.suPAr in severe sepsis
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did  not  include  follow-up  measurement  after  full 
recovery but it has been demonstrated in clinical trials 
that effective treatment of infectious diseases resulted 
in a decrease in suPAR levels after full recovery.15,16
Supporting  previous  findings3,10,13  suPAR  levels 
were correlated to SOFA scores in patients with severe 
sepsis (P = 0.05, r = 0.43). The SOFA score is a sep-
sis mortality risk algorithm including multiple labora-
tory and clinical measures and is based on six different 
scores,  one  each  for  the  respiratory,  cardiovascular, 
hepatic, coagulation, renal and neurological systems. 
It was surprising that suPAR levels did not correlate 
directly with mortality, only with severity. A probable 
explanation is the low number of patients in the present 
study (n = 27, ICU mortality = 44%), since several large 
studies have shown good correlation between high lev-
els of suPAR and mortality in sepsis patients.11–13
At present, it is unclear whether plasma suPAR 
actually exerts proinflammatory actions or if it just 
reflects  general  inflammation.  Further  studies  are 
needed for a satisfying understanding of the   regulatory 
mechanisms of suPAR in order to evaluate whether 
suPAR could be a potential novel therapeutic target in 
critically ill patients. In the present study suPAR lev-
els were not correlated with the non-specific inflam-
matory  markers  CRP  and  PCT  in  sepsis  patients, 
which is consistent with another study.8 Neither did 
suPAR correlate with the proinflammatory cytokine 
IL-6 nor the anti-inflammatory cytokine IL-10. The 
correlation between suPAR and MPO suggests that 
suPAR  reflects  activation  of  the  cellular  immune 
system rather than exerting proinflammatory or anti-
  inflammatory actions.
In conclusion, plasma levels of suPAR are increased 
in sepsis patients upon admission to the ICU, likely 
reflecting the activation state of the immune system, 
and remain elevated during the first four days of treat-
ment. The suPAR level appears to have almost equal 
prognostic value as admission SOFA scores. The fact 
that suPAR did not significantly correlate with mor-
tality may be explained by the relatively low num-
ber of patients included in this study (n = 27, ICU 
mortality = 44%).
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